TNF Pharmaceuticals (NASDAQ:TNFA) Sees Large Volume Increase - What's Next?

Key Points

• TNF Pharmaceuticals experienced a significant trading volume increase of 31%, with 283,272 shares traded, while the stock price dropped to $3.75.
• The company reported a loss of $18.00 EPS in its latest quarterly earnings results, highlighting financial challenges despite its drug development focus.
• With a market cap of $613.56 million and a PE ratio of -1.49, TNF Pharmaceuticals operates as a clinical-stage firm targeting chronic inflammation through its MYMD-1 drug platform.

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA - Get Free Report) shares saw strong trading volume on Wednesday . 283,272 shares changed hands during mid-day trading, an increase of 31% from the previous session's volume of 215,501 shares.The stock last traded at $3.75 and had previously closed at $3.80.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised TNF Pharmaceuticals to a "sell" rating in a research report on Friday.

TNF Pharmaceuticals Stock Down 8.6%

The company has a 50 day moving average price of $9.96 and a 200-day moving average price of $21.10. The company has a market cap of $5.91 million, a price-to-earnings ratio of -0.01 and a beta of 2.04.

TNF Pharmaceuticals (NASDAQ:TNFA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 19th. The company reported ($18.00) earnings per share for the quarter.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.